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Paediatric acquired demyelinating 
syndromes: incidence, clinical and  
magnetic resonance imaging features
Michael Absoud1, Ming J Lim2, Wui K Chong3,  
Christian G De Goede4, Katharine Foster5, Roxana Gunny3, 
Cheryl Hemingway6, Philip E Jardine7, Rachel Kneen8,  
Marcus Likeman9, Ken K Nischal10, Michael G Pike11,  
Naomi A Sibtain12, William P Whitehouse13, Carole Cummins1* 
and Evangeline Wassmer14* for The UK and Ireland Childhood 
CNS Inflammatory Demyelination Working Group
Abstract
Objective: Changing trends in multiple sclerosis (MS) epidemiology may first be apparent in the childhood population 
affected with first onset acquired demyelinating syndromes (ADSs). We aimed to determine the incidence, clinical, 
investigative and magnetic resonance imaging (MRI) features of childhood central nervous system ADSs in the British 
Isles for the first time.
Methods: We conducted a population active surveillance study. All paediatricians, and ophthalmologists (n = 4095) 
were sent monthly reporting cards (September 2009–September 2010). International Paediatric MS Study Group 2007 
definitions and McDonald 2010 MS imaging criteria were used for acute disseminated encephalomyelitis (ADEM), clinically 
isolated syndrome (CIS) and neuromyelitis optica (NMO). Clinicians completed a standard questionnaire and provided 
an MRI copy for review.
Results: Card return rates were 90%, with information available for 200/222 positive notifications (90%). After exclusion 
of cases, 125 remained (age range 1.3–15.9), with CIS in 66.4%, ADEM in 32.0% and NMO in 1.6%. The female-to-male 
ratio in children older than 10 years (n = 63) was 1.52:1 (p = 0.045). The incidence of first onset ADS in children aged 
1–15 years old was 9.83 per million children per year (95% confidence interval [CI] 8.18–11.71). A trend towards higher 
incidence rates of ADS in children of South Asian and Black ethnicity was observed compared with White children. 
Importantly, a number of MRI characteristics distinguished ADEM from CIS cases. Of CIS cases with contrast imaging, 
26% fulfilled McDonald 2010 MS diagnostic criteria.
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Introduction
Multiple sclerosis (MS) is a chronic disabling and costly 
neurodegenerative disorder. Incidence of MS appears to be 
increasing worldwide with a rising female-to-male sex 
ratio,1,2 and with approximately 5% of adults who develop 
MS having first symptoms in childhood.3,4 Some epidemio-
logical evidence suggests early environmental exposures 
may influence MS risk.5,6 Hence, any epidemiological 
change in MS may be evident first in a paediatric 
population.
Diagnosis of MS in children, as in adults, is first her-
alded by onset of a clinically isolated syndrome (CIS), or 
more rarely acute disseminated encephalomyelitis 
(ADEM). Children diagnosed with relapsing–remitting MS 
present with one of the central nervous system (CNS) 
acquired demyelinating syndromes (ADS) followed by a 
second event usually within 2 years.7 Childhood CIS pres-
entations with an abnormal magnetic resonance imaging 
(MRI) of the brain (i.e. more than one high T2 signal) com-
pared with ADEM are more likely to have relapsing dis-
ease.8-12 Recently, the new MRI McDonald 2010 MS 
criteria have been recommended for use in children pre-
senting with a CIS,13 potentially allowing for MS diagnosis 
at first presentation of a CIS.14 There is no biomarker that 
differentiates between monophasic ADEM, monophasic 
CIS, or MS, hence a combination of clinical, cerebrospinal 
fluid (CSF) positive oligoclonal bands and MRI features is 
suggested.12, 15 MRI differences, in particular between 
ADEM and polyfocal CIS, are also not well recognized.16 
The differential diagnosis of ADS is complex and wide, 
especially so in childhood.17
The International Paediatric Multiple Sclerosis Study 
Group (IPMSSG) have published consensus definitions 
(2007) of paediatric CNS ADS and MS to facilitate uni-
formity in clinical practice and future epidemiological 
research.4 Two previous surveillance studies in Canada 
(2004–2007) and Germany (1997–1999) revealed an inci-
dence ranging from 3.718 to 9.0 per million children per 
year.19 The incidence of childhood ADS remains largely 
unknown worldwide, and as the incidence of these disor-
ders based on the epidemiology of MS in adults is likely to 
differ geographically, estimates are needed from multiple 
geographical regions.
We report a multinational multisource20 prospective 
active surveillance study in the British Isles (latitudes 
50–59°N) to ascertain incidence, clinical, investigative and 
MRI features of childhood (age <16 years) ADS using 
panel review to apply IPMSSG consensus definitions 
(including the incorporated McDonald MRI 2001 and 
Barkhof space diagnostic criteria).4, 21 We also apply the 
newly revised 2010 McDonald space and time diagnostic 
criteria at first ADS presentation;13 and the recent Verhey 
MRI prognostic MS criteria.22
Methods
Study design
We carried out a prospective active surveillance study of 
first episode ADS in children aged between 1 and 15 years 
11 months of age, in the British Isles. We used multisource 
ascertainment via two well-established surveillance units in 
order to establish incidence of new cases.
The British Paediatric Surveillance Unit 
(BPSU), the primary source of data
The British Paediatric Surveillance Unit (BPSU) facilitates 
epidemiological surveillance of childhood diseases of pub-
lic health importance in the UK and Republic of Ireland. 
The BPSU, launched in 1986, has helped initiate over 80 
studies with a card return rate consistently higher than 93%.
The British Ophthalmological Surveillance 
Unit (BOSU), the alternative source of data 
for optic neuritis cases
The British Ophthalmological Surveillance Unit (BOSU) 
enables ophthalmologists to participate in the nationwide 
surveillance of uncommon ophthalmological conditions. 
The BOSU card return rate is consistently higher than 75%.
Case ascertainment via active surveillance
One month before commencing the study, a protocol card 
and letter was sent to all clinicians informing them of the 
study. Monthly notification cards (mean 4095/month) were 
sent by the BPSU (mean 2945/month) to all registered cer-
tified consultant paediatricians and paediatric neurologists 
Conclusions: We report the highest surveillance incidence rates of childhood ADS. Paediatric MS diagnosis at first ADS 
presentation has implications for clinical practice and clinical trial design.
Keywords
pediatric multiple sclerosis, paediatric multiple sclerosis, acute disseminated encephalomyelitis, demyelination, demyelinating, 
pediatric, paediatric, childhood, adolescent, epidemiology, incidence, magnetic resonance imaging
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and BOSU (mean 1150/month) to all registered ophthal-
mologists (between September 2009 and September 2010). 
In the British Isles, these clinicians are likely to see all 
cases of childhood ADS. Clinicians returned the card to the 
surveillance units notifying any cases or confirming ‘noth-
ing to report’. Upon receipt of a positive notification the 
surveillance units provided the investigating team with a 
BPSU/BOSU case number and clinician contact details. 
The study team contacted the clinician directly, sending a 
detailed data collection form and a blank CD for an 
anonymized MRI. As more than one clinician might notify 
the same patient seen in different settings, minimal identi-
fiers (National Health Service [NHS] number, district post-
code, sex and date of birth) were used for record linkage 
and to exclude duplicates with a high level of certainty 
(http://www.rcpch.ac.uk/bpsu).
Initial surveillance reports
Using the IPMSSG consensus definitions for classification 
of paediatric ADS,4 we asked clinicians to report children 
experiencing clinical neurological events consistent with a 
first episode ADS and confirmed with white matter changes 
(except in optic neuritis) on MRI (Table 1).
Data collection
A condition specific targeted neurological history was col-
lected at the time of first demyelinating event. Data col-
lected included: basic demographic data; demyelinating 
symptoms and signs; CSF findings, serological and 
microbiological results; timing of MRI being carried out 
and whether abnormal; and treatment given.
MRI imaging review
MRI scans were reviewed blinded to clinical features by MA 
and one of five neuroradiologists (KC, KF, RG, ML, NS). A 
standardized proforma was completed utilizing previously 
described nomenclature (supplementary material appendix 
1).10, 23, 24 McDonald 2001 dissemination in space criteria (as 
recommended by the current IPMSSG criteria),4, 21 McDonald 
2010 dissemination in space and time (if a gadolinium-
enhanced scan was available) criteria and Verhey prognostic 
criteria were classified by MA according to the MRI variables 
and associated panel review.13 Features of ADEM and CIS 
scans were compared. Although a single MRI protocol was 
not feasible as this was a national population based study col-
lecting data from established clinical practice from all cen-
tres, all MRI brain scans were performed on 1.5 T scanners 
and had a minimum of a T1-weighted and a T2-weighted or 
fluid-attenuated inversion recovery (FLAIR) sequence in two 
different planes. Additional sequences included gadolinium-
enhanced T1, diffusion weighted and spine images. MRI slice 
thickness varied from 3–5 mm.
Panel classification and agreement for 
inclusion
The co-investigators met quarterly as a panel to review 
reported cases (at least four members present at each meet-
ing). The panel consisted of paediatric neurologists (n = 8; 
Table 1. Summarized inclusion definitions for CNS acquired demyelinating syndromes.
Condition Definition
Acute disseminated 
encephalomyelitis 
(ADEM)
(1) A polysymptomatic clinical event with acute/subacute onset that must include encephalopathy 
(behavioural change or altered consciousness). (2) MRI brain shows multifocal lesions.
Clinically isolated 
syndrome (CIS)
A first acute-clinical episode of CNS symptoms which may either be monofocal or multifocal, but does not 
include encephalopathy (except in brainstem syndromes). The MRI will show white matter demyelination. 
These include:
1.  Transverse myelitis (TM): weakness and/or numbness of both legs +/- arms, usually with maximal deficits  
1 week after symptom onset supported by demyelination on MRI spine.
2.  Optic neuritis: Acute or subacute loss of vision and ≥1 of: relative afferent pupillary defect (unilateral 
cases), visual field deficit or scotoma, impaired colour vision, optic disc oedema, or abnormal visual 
evoked potentials. MRI is not necessary for diagnosis.
3.  Other CIS: Brainstem, cerebellar, and/or hemispheric dysfunction, supported by demyelination on MRI.
Neuromyelitis optica 
(NMO)
Must have: i. Optic neuritis and ii. Acute myelitis.
Must have: iii. Spinal MRI lesion extends over three or more segments or iv. Aquaporin-4 antibody testing is 
positive.
The brain MRI may be abnormal but must not meet Multiple Sclerosis MRI diagnosis criteria.
Exclusion criteria 1.  Leukodystrophies (e.g. metachromatic leukodystrophy, adrenoleukodystrophy) or mitochondrial disease.
2.  Proven CNS infection (e.g. viral encephalitis, bacterial meningitis, herpes simplex encephalitis, Lyme 
disease, HIV).
3.  Radiation/chemotherapy associated white matter damage.
4.  Condition fulfilling criteria for CNS connective tissue disease e.g. lupus, vasculitis. The sole presence of 
antibodies associated with CNS connective tissue or autoimmune diseases was not sufficient for exclusion.
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CDG, CH, EW, MJL, MP, PJ, RK, WPW) with expertise in 
ADS, and final classification as per IPMSSG clinical criteria 
was arrived at by consensus. MRI images (with neuroradiolo-
gist scoring) were used to confirm the presence of lesions 
consistent with inflammatory demyelination, to aid in the 
exclusion of cases and to sub-classify CIS cases with asymp-
tomatic MRI lesions (supplementary material appendix 1).17
Statistical analysis
Descriptive statistics were used to summarize the key com-
ponents of the dataset. Estimates of national incidence with 
confidence intervals (Byar’s approximation of the exact 
Poisson) for the 13-month study was annualized using mid-
2010 UK and 2010 Republic of Ireland population esti-
mates.25,26 Mid-2009 population estimates by ethnicity for 
England and Wales were used to evaluate rates of child-
hood ADS by ethnicity (Table 2). A sensitivity analysis was 
conducted on a worst-case scenario that all reported cases 
with missing clinical histories were actually cases of ADS 
to assess the potential impact on estimated incidence of 
ADS. We used a two source case capture–recapture analy-
sis to estimate missed cases of optic neuritis on the assump-
tion of independence,27 but did not carry out 
capture–recapture analysis for other ADS, as referral net-
works mean that the assumption of independence was vio-
lated. The England 2010 index of multiple deprivation was 
used to derive the percentage of cases in England living 
in the 20% most deprived districts.28 Parametric or non-
parametric statistical tests (Kruskal–Wallis tests) were used 
for continuous distributions as appropriate given normality 
and χ2 or Fisher’s exact tests for nominal data. Agreement 
between reporters and the panel was measured using the 
Kappa statistic. Statistical analysis was performed using 
PASW Statistics for Windows version 17.0 (© SPSS, Inc., 
2009, Chicago, IL, www.spss.com) and the openepi soft-
ware (version 2.3.1, www.openepi.com).29
Approvals
The study was approved by the BPSU and BOSU executive 
committees. Data handling was restricted to those with 
direct involvement in the project. To comply with collec-
tion of minimal identifier information regulations without 
patient consent as in Section 251 of the NHS Act 2006, the 
study has approval from the National Information 
Governance Board’s Ethics & Confidentiality Committee 
(ECC/BPSU 4-03[FT1]/2009) and the UK Multicentre 
Research Ethics Committee (09/H1202/92).
Results
Card return rate, expert review and record 
linkage outcome
Card return rate was 94% from the BPSU and 78% from the 
BOSU (total 47,910 from 53,235 cards returned including 
negative reports). There were 222 positive notifications 
(197 BPSU and 25 BOSU) with insufficient information 
for review of 22 notifications (6 Scotland, 12 England and 
Wales, and 4 Ireland and Northern Ireland). In the remain-
ing 200 (90%), 41 duplicate notifications were identified. 
Cases where the event was outside the inclusion dates, 
September 2009 to September 2010 (n = 16) were excluded. 
A further 18 cases were excluded by the panel (Figure 1). A 
Table 2. Incidence of childhood CNS acquired demyelinating syndromes by country, sensitivity analysis and ethnic group in England 
and Wales.
CONFIRMED CASES
Region Number Percentage Population 2010 1–15 
years (per thousands) or %
Incidence per  
annum per million
95% CI 
lower
95% CI 
upper
England, Wales and Channel Islands 117 93.6 9636 11.2 9.27 13.4
Scotland 3 2.4 853 3.25 0.65 9.49
Ireland and Northern Ireland 5 4.0 1254 3.68 1.19 8.59
Total 125 100.0 11743 9.83 8.18 11.71
Sensitivity Analysis Assuming All Reports With Missing Information Are Cases
England, Wales and Channel Islands 129 87.8 9636 12.36 10.32 12.68
Scotland 9 6.1 853 9.74 4.44 18.5
Ireland and Northern Ireland 9 6.1 1254 6.63 3.0 12.6
Total 147 100.0 11743 11.6 9.76 13.6
Incidence By Ethnicity In England And Wales
White 93 80.17% 83.93% 10.62 8.57 13.00
South Asian: Indian; Pakistani;  
Bangladesh; other South Asian background
11 9.48% 7.30% 14.43 7.20 25.83
Black 7 6.03% 3.31% 20.25 8.12 41.73
Chinese, mixed and other 5 4.31% 5.46% 8.78 2.82 20.27
Total 116 116 100%  
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total of 124/125 cases remaining had MRI scans (one iso-
lated optic neuritis had no MRI scan, four transverse myeli-
tis cases had MRI spine only).
Incidence of childhood CNS inflammatory 
demyelination in the British Isles
The minimum incidence of first onset ADS in children aged 
1–15 years old in the British Isles is 9.83 per million 
children per year (95% confidence interval [CI] 8.18–11.71). 
Incidence was highest in England and Wales (Table 2). A 
sensitivity analysis showed no significant difference in inci-
dence rates within countries in the British Isles.
Demographic characteristics
Median age was 10.0 years (range 1.3–15.9; mean 9.74 
years, SD 4.34) and 51.2% (n = 64) of cases were female 
Figure 1. Study flow chart showing panel review and record linkage outcome.
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(Table 3). The median age for males was 8.9 years (inter-
quartile range [IQR] 5.0–13.5) and for females was 11.4 
years (IQR 6.8–14.4; p = 0.046). The female-to-male ratio 
in children younger than 10 years (n = 62) was 0.72:1 and 
in older than 10 years (n = 63) was 1.52:1. White children 
comprised 81% of the cohort. Higher incidence rates of 
ADS in children of South Asian and Black ethnicity in 
England and Wales compared with White children were 
observed, although not reaching statistical significance 
(Table 2). A total of 34% of the cases in England lived in 
the most 20% deprived districts. Children living in the most 
20% deprived areas were more likely to be males compared 
with female (23:13) when compared with those living in 
the 80% least deprived areas (30:40, p = 0.040). They were 
also most likely to be of non-White ethnicity (12:24 versus 
11:58, p = 0.041). Age and ADS presentation did not influ-
ence those living in the most 20% deprived areas.
Results of panel review and clinical 
classification
Childhood ADS were classified as CIS in 66.4%, ADEM in 
32.0% and neuromyelitis optic (NMO) in 1.6%. Of the CIS 
cases, optic neuritis (ON) represented 37.4%, transverse 
myelitis (TM) 31.3% and other CIS 31.3% (Table 3). The 
majority (70%) of the other CIS cases were polysympto-
matic. Children with ADEM were younger than cases pre-
senting with CIS (p < 0.001) (Figure 2). The risk ratio for 
CIS in females compared with males was 1.46 (95% CI 
1.17–1.83). The panel reclassified a total of 15 out of the 
Table 3. Clinical, demographic, and phenotypic expert panel classification of the childhood CNS acquired demyelinating syndromes.
CIS (n = 83)
 ADEM (n = 40) ON (n = 31) TM (n = 26) Other CIS (n = 26) NMO (n = 2)
Age at presentation: median 
(IQR)
5.3 (3.6-7.0) 11.8 (9.0-13.9) 12.6 (9.3-14.0) 14.0 (9.5-14.5) 6.4 and 14.8 years
Sex (n = 125) Male: Female  
(% female) 61: 64 
(51%)
24:16 (40%) 15:16 (52%) 11:15 (58%) 11:15 (58%) 0:2 (100%)
 37:46 (55%)
Ethnicity  
(n = 124/125)
White (n = 101)
Asian (n = 11)
36 (90%)
3
21 (68%)
4
22 (85%)
2
21 (81%)
1
1 (50%)
1
 Black (n = 7) 1 3 1 2 0
 Chinese, mixed, 
other (n = 5)
0 3 1 1 0
Clinical: MRI:  
Monofocal ≥ 1 asymptomatic 
lesion
7 (23%) 9 (35%) 4 (15%)  
 no asymptomatic 24 17 3 (12%)  
Multifocal ≥ 1 asymptomatic 0 0 16 (62%)  
 no asymptomatic 0 0 2 (8%)  
Radiologically isolated n/a n/a 1  
Spinal lesion(s) present: n (% ≥ 3 
segments)
8/12 (100%) 1/8 (0) 26/26 (62%) 4/9 (75%) 2/2 (100%)
Death 1/40 (2.5%) 0 0 0 0
Seizures 8/40 (20%) 0 0 0 0
Optic neuritis: Unilateral: bilateral 
(% bilateral)
0:3 (100%) 22:9 (29%) 0:0 0:1 1:1 (50%)
Cerebellar signs: n (%) 18 (45%) 0 0 11 (42%) 0
Brain stem signs: n (%) 11 (28%) 0 1 13 (50%) 0
Pyramidal signs: n (%) 24 (60%) 0 0 10 (38%) 0
Intensive care unit admissions; n 
= 12 (10%)
8 (20%) 0/31 (0%) 3/26 (12%) 1/26 (4%) 0/2
Plasma exchange; n = 4 (3%) 2 (5%) 0/31 2/26 (8%) 0/26 0/2
Intravenous corticosteroids 37/40 (93%) 23/31 (74%) 25/26 (96%) 18/26 (69%) 2/2 (100%)
Oral steroids 27/40 (68%) 21/31 (67%) 16/26 (62%) 11/26 (42%) 2/2 (100%)
Intravenous immunoglobulin 6/40 (15%) 0 7/26 (27%) 1/26 (4%) 0
ADEM, acute disseminated encephalomyelitis; ON, optic neuritis; TM, transverse myelitis; CIS, clinically isolated syndrome; NMO, neuromyelitis optica; 
MRI, magnetic resonance imaging; IQR, interquartile range.
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125 cases (12%): ADEM to CIS (n = 11) mainly due to lack 
of encephalopathy; Other CIS to TM (n = 3); TM to other 
CIS (n = 1). The overall level of agreement between report-
ers and the panel was good (Kappa 0.838 [95% CI 
0.761–0.914]).
Deaths
Clinicians reported three deaths in the initial hospital 
admission, one in a child with ADEM and two in cases 
which proved not to have ADS (post-transplant lymphopro-
liferative disorder and hypereosinophilic syndrome).
Capture–recapture analysis
Capture–recapture analysis for ON cases (n = 31) assuming 
that BPSU and BOSU were independent sources of cases 
estimated the total population to be 47 (95% CI 30–55).
MRI features
More CIS cases fulfilled MRI McDonald 2010 dissemina-
tion in space criteria (42%) compared with the 2001 criteria 
(28%; Table 4). Of the CIS cases which had contrast-
enhanced scans (n = 38), 10 cases (26%) fulfilled McDonald 
2010 space and time criteria for MS diagnosis. Verhey MRI 
prognostic criteria for identifying childhood ADS at high 
risk of MS (presence of one T1 hypointense and one perive-
ntricular lesion) were fulfilled in 11/78 (14%) CIS cases 
compared with 1/40 (2.5%) ADEM cases. A total of 19/78 
(24%) CIS cases fulfilled either Verhey prognostic criteria 
or McDonald 2010 MS space and time criteria for MS (8/10 
cases which fulfilling McDonald 2010 space and time cri-
teria did not fulfil Verhey criteria, whilst 3/5 fulfilling 
Verhey criteria did not fulfil McDonald criteria).
ADEM cases compared with CIS cases with abnormal 
MRI (supplementary material appendix 2) were more likely 
to have more deep grey nuclei (p < 0.001), large white mat-
ter (p < 0.001) and cortical grey matter (p = 0.001) high T2 
signal lesions. CIS scans were more likely to have more 
periventricular (p < 0.001), deep white matter (p = 0.003), 
corpus callosum (p = 0.001), well-defined and discrete high 
T2 signal lesions (p < 0.001) and black holes (p = 0.008). 
The number of total high T2 signal, enhancing, infratento-
rial, juxtacortical and spinal lesions did not differentiate 
between CIS and ADEM patients. Of the ON and TM cases 
(monofocal CIS) 23% and 35% had one or more high T2 
signal brain lesion respectively (Table 3). 
Investigative features
Children with ADEM more commonly had CSF lympho-
cytosis (p = 0.005) and less commonly CSF positive oli-
goclonal bands (p = 0.011) compared with those with CIS 
(Table 5). One ADEM case was reported as having the 
common missense mutation (c.1880CT, p.Thr585Met) 
of the Ran Binding Protein 2 (RANBP2) gene previously 
reported in recurrent or familial 
Figure 2. Childhood acquired demyelinating syndromes by age 
(younger and greater than 10 years old) and sex.
Table 4. MRI criteria fulfilled.
Panel classification
CIS (n = 83)
ON (n = 31) TM (n = 26) Other CIS (n = 26)
McDonald 2001 space criteria 4/30  5/22 13/26
22/78 (28%)
McDonald 2010 space criteria 5/30  8/22 20/26
 33/78 (42%)
McDonald 2010 time criteria (gadolinium given scans) 0/12  3/11  7/15
10/38 (26%)
Meets McDonald MRI criteria for MS on initial presentation
(dissemination in space and time)
10/38 (26%)
Verhey or McDonald 2010 MS criteria present 19/78 (24%)
MRI, magnetic resonance imaging; MS, multiple sclerosis; ON, optic neuritis; TM, transverse myelitis; CIS, clinically isolated syndrome.
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acute necrotising encephalopathy.30 Of those tested for the 
aquaporin-4 antibody (n = 52), none of the ADEM (n = 5), 
TM (n = 20), and other CIS (n = 7) cases tested positive while 
one child with ON and both NMO patients tested positive.
Treatment
The majority (89%) received either intravenous corticoster-
oids (84%) and/or oral prednisolone in the first instance. A 
higher proportion of children with ADEM were required 
intensive care unit (ICU) admission, and four children (two 
ADEM and two TM) received plasma exchange. 
Intravenous immunoglobulin was administered to 11% of 
the cohort (Table 3).
Discussion
The minimum incidence of first onset childhood ADS in 
the British Isles is 9.83 per million (95% CI 8.18–11.71) 
children per year aged 1–15 years. This is the highest 
reported incidence of childhood ADS from a prospective 
childhood surveillance study. To date, there have been two 
surveillance studies studying ADS. A Canadian surveil-
lance study (2004–2007) estimated the incidence of child-
hood ADS to be 9.0 per million people aged less than 18 
years old,19 with 22% classified as ADEM and 78% as CIS. 
Although this study did not have MRI review and was con-
ducted prior to the IPMSSG consensus definitions, it is 
unlikely that these factors would have had a major influ-
ence on classification. An earlier surveillance study from 
Germany (1997–1999) estimated the incidence of MS in 
children <16 years as 3.0 per million children, and that of 
ADEM as only 0.7 per year per million children aged less 
than 16 years old.18 This study asked clinicians to report 
new cases of definite or suspected MS or ADEM cases, and 
did not include other ADS. Diagnosis of MS and ADS 
depends on clinical definitions and MRI criteria used, and 
hence it may be that these ascertainment estimates would 
change with current definitions and criteria (supplementary 
material appendix 3).
The mean age of onset (9.7 years) was similar to the 
Canadian incidence study (mean 10.5 years) and a French9 
(children <16 years, 1985-2001) first episode ADS retro-
spective cohort study (mean 9.9 years), but older than a 
Dutch10 (children <16 years, 1990–2010) retrospective 
cohort study (8.5 years). A recent retrospective study from 
the USA (n = 85) showed the incidence of childhood ADS 
and MS to be higher in Black children compared with White 
and Hispanic children.31 While non-White ethnic groups 
were over-represented in our study (n = 125), this did not 
reach statistical significance. Although there is limited 
power to compare subgroups in the study, this still contrasts 
with the adult MS population where white ethnic groups are 
over-represented. Adult and paediatric7,14,32 MS studies have 
shown that adolescent females are over-represented com-
pared with males with ratios of up to 3:1. An adult CIS study 
has also shown a higher risk ratio of females developing 
CIS,33 the first presentation of MS. Our study shows that in 
childhood first onset ADS, sex ratios also varied with age, 
with more females in the older age groups (F:M ratio of 
1.52:1 in children over 10 years). Children older than 10 
years more often had CIS compared with those less than 10 
years of age who presented more often with ADEM. A 
Japanese retrospective multicenter study showed the male-
to-female ratio of ADEM to be 2.3:1, and that ADEM was 
three times more common than MS.34 In addition previous 
UK epidemiological adult studies have shown that MS hos-
pital admissions, incidence and prevalence were higher in 
those living in least deprived areas. 35,36 Our study showed 
that children with ADS living in the most 20% deprived 
areas (in England) were more likely to be males and of non-
White ethnicity. These observations regarding the geo-
graphical deprivation indices and demographics of 
childhood ADS (over-representation of older females with 
CIS, and children with Black and South Asian ethnicity) add 
further support to the hypothesis that environmental influ-
ences may indeed be acting as early as in childhood.
This study is not without limitations. As with other epi-
demiological studies, some cases may not have been 
reported or have had sub-clinical presentations, and it is 
plausible that children in our study who met McDonald 
Table 5. Investigative features.
Expert panel classification
ADEM (n = 40) CIS (n = 83) NMO (n = 2)
ON (n = 31) TM (n = 26) Other CIS (n = 26)
CSF oligoclonal bands 2/20 (10%) 6/17 (35%) 6/19 (32%) 10/15 (67%) 0/1 (0%)
CSF WBC ≥5 × 106/l 21/36 (58%) 3/17 (18%) 8/20 (40%) 8/21 (38%) 0/2 (0%)
CSF protein median (IQR) 0.38 (0.25–0.58)
n = 28
0.26 (0.23–0.35)
n = 17
0.36 (0.26–0.52)
n = 19
0.29 (0.21–0.36)
n = 17
0.29
n = 2
Genetic tests reported 1 case RANBP2 positive n/a n/a n/a n/a
ADEM, acute disseminated encephalomyelitis; ON, optic neuritis; TM, transverse myelitis; CIS, clinically isolated syndrome; NMO, neuromyelitis optica; 
CSF, cerebrospinal fluid RANBP2, Ran Binding Protein 2 gene; IQR, interquartile range; WBC, white blood cell.
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2010 criteria for MS at first clinical presentation may have 
had previous symptoms not identified as ADS. This was 
addressed as far as was possible by using clear consensus 
case definitions and multiple sources of case ascertainment. 
A capture–recapture analysis estimated that a possible 16 
ON cases were missed out of a potential 47, although this 
relies on assumptions of complete independence that may 
not hold in practice.
Our study shows that childhood CIS occurs more often 
than ADEM (ratio 2.1:1) and also confirms a previous 
report that ADEM can be a severe disease with one death 
and one in five requiring intensive care admission.37 The 
proportion of children with ADEM in our cohort (32%) was 
slightly higher than French9 (29%), Canadian (22%), and 
Dutch10 cohorts (termed polyfocal ADS with encephalopa-
thy, not ADEM).
We found that 43% of CIS patients had one or more 
asymptomatic brain lesion. Previous studies have shown 
that children with CIS with abnormal brain scans are at a 
higher risk of relapse than those without asymptomatic 
brain lesions.11,12 Also it is of interest that a number of MRI 
measures significantly helped differentiate ADEM from 
CIS cases. For example, ADEM cases compared with CIS 
had more deep grey nuclei and cortical grey matter high T2 
signal lesions. CIS cases had more periventricular, deep 
white matter, corpus callosum high T2 signal lesions and 
black holes.
CSF lymphocytosis and negative oligoclonal bands 
were associated with an ADEM diagnosis, in contrast to a 
previous study.16 It is of interest that one case was reported 
as positive for the common mutation in the RANBP2 gene, 
which has been recently described in familial or recurrent 
acute necrotizing encephalopathy (ANE).30 With the 
increasing recognition of the overlap between the MRI and 
clinical features of ADEM and ANE, and further reports of 
other genetically predetermined encephalopathies,38 this 
potential novel group of genetic determinant(s) of encepha-
lopathy in demyelination requires exploration.
A total of 26% of CIS cases who had gadolinium given 
scans (n = 38) fulfilled McDonald 2010 MRI criteria for 
MS at onset (space and time), hence a minimum 12% of 
CIS patients met McDonald 2010 MS diagnostic criteria at 
diagnosis. In addition 24% of CIS cases fulfilled either 
McDonald 2010 or Verhey criteria which are thought to 
indicate higher risk of MS, although both the McDonald 
criteria and the Verhey model require further validation in 
prospective multinational cohorts. This is particularly the 
case as in this study 8/10 of cases fulfilling McDonald 2010 
MS criteria did not meet the criteria from Verhey’s predic-
tive model. We have previously shown that 61% of children 
eventually diagnosed with MS and who had contrast-
enhanced scans at ADS onset fulfilled McDonald 2010 MS 
criteria at first scan.14 Not all children in this study had spi-
nal imaging and contrast administered, and MRI sequence 
variation could have affected the sensitivity of MRI.
The potential to diagnose MS at disease onset has impli-
cations for MRI protocols for children with suspected ADS, 
and individual patient treatment decisions. This may be 
particularly important as new MS drugs are emerging with 
reported better efficacy in adults than current injectables, 
and the simultaneous requirement for new drugs to undergo 
testing in children with the aim of ensuring robust evidence 
to support authorization by regulatory agencies. To date, 
eight new MS drugs have been recommended for a 
Paediatric Investigation Plan,39 hence earlier diagnosis may 
increase the eligible clinical trial population. Prognostic 
and outcome data are needed to inform these decisions. A 
prospective 2-year follow up of this patient cohort is under 
way and a further multicentre cohort study with detailed 
outcome measurements and a biobank have been estab-
lished.40 These should yield prognostic information and aid 
validation of consensus definitions, and the clinical utility 
of the new McDonald and Verhey proposed MRI criteria 
for early diagnosis of MS in children.
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